did the fda stop semaglutide crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many Despite FDA ruling, compounded GLP-1s

In a combined fertility and prenatal and postnatal study of another insulin glargine product in male and female rats at subcutaneous doses up to 0.36 mg/kg/day, which was approximately 7 times the recommended human subcutaneous starting dose of 10 units/day (0.008 mg/kg/day), based on mg/m2, maternal toxicity due to dose-dependent hypoglycemia, including some deaths, was observed

Increased scale of manufacturing, efficient cold-chain logistics, and increasing investments by biopharma stakeholders reduces unit cost and increases geographic presence, especially into previously underpenetrated emerging markets, thus, solidifying clinical partnerships and distribution networks

PMCID: PMC10999838

Current status and trends in small nucleic acid drug development: leading the future